SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
High Dose of Gilead and Galapagos’ JAK-Inhibitor Filgotinib Hits the Mark in UC Study
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
May 21, 2020
 · 
2 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: May 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
May 21, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Atea Pharma to Launch Phase II Trial Against COVID-19 After Raising $215 Million Series D
In addition to the COVID-19 development, the company plans to use the proceeds toward its pipeline of highly selective direct acting antivirals that target other severe RNA virus infections.
May 20, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 20
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
May 20, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 19, 2020.
May 19, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 18
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
May 18, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Bio NC
Clinical Catch-Up: May 11-15
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
May 15, 2020
 · 
12 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 15
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 15, 2020.
May 15, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
nitpicker / Shutterstock
Drug Development
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
Bristol Myers Squibb released new data from two clinical trials of Opdivo plus Yervoy-based combinations in non-small cell lung cancer and updated results from the KarMMa trial of ide-cel for multiple myeloma being developed with bluebird bio.
May 14, 2020
 · 
2 min read
 · 
Mark Terry
Drug Development
Genentech’s Double Checkpoint Inhibitor Combo Shows Promise in Lung Cancer
Genentech, a Roche company, announced positive results from the Phase II CITYSCAPE clinical trial in PD-L1-positive metastatic non-small cell lung cancer.
May 14, 2020
 · 
2 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Drug Development
Lutris Pharma Announces Publication of Positive Data From Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer
February 21, 2024
 · 
7 min read
Drug Development
Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies
February 21, 2024
 · 
5 min read
Drug Development
Calian Wins Contract to Support Clinical Trial for ZYUS Life Sciences’ Lead Drug Product Candidate
February 20, 2024
 · 
5 min read
Drug Development
Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer
February 20, 2024
 · 
6 min read
Drug Development
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIb Trial with Nadunolimab
February 20, 2024
 · 
3 min read
Drug Development
Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson’s Disease with its NLRP3 Inhibitor, Dapansutrile
February 20, 2024
 · 
10 min read
Drug Development
Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis
February 20, 2024
 · 
3 min read
Drug Development
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
February 20, 2024
 · 
4 min read
Drug Development
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
February 20, 2024
 · 
4 min read
Drug Development
Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® Liquid
February 20, 2024
 · 
5 min read
Drug Development
Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments
February 20, 2024
 · 
4 min read
Drug Development
Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.
February 19, 2024
 · 
2 min read
Drug Development
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure
February 16, 2024
 · 
10 min read
Drug Development
Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses
February 15, 2024
 · 
5 min read
Drug Development
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS
February 15, 2024
 · 
8 min read
Drug Development
Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
February 14, 2024
 · 
5 min read
Drug Development
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
February 14, 2024
 · 
3 min read
Drug Development
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
February 14, 2024
 · 
5 min read
Drug Development
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
February 14, 2024
 · 
4 min read
Drug Development
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
February 14, 2024
 · 
3 min read
Load More